In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci

International Journal of Antimicrobial Agents

Volumn 23, Issue 3, 2004, Pages 247-253

  Bergeret, M ^a   Boutros, N ^a   Raymond, J ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Cefpirome; Coagulase negative staphylococci; Decreased susceptibility to glycopeptides; GISA

Indexed keywords

CEFPIROME; GLYCOPEPTIDE; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENTIATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS;

EID: 1442287485     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.08.009     Document Type: Article

References (39)

1. Friedman L.E., Brown A.E., Miller D.R., Armstrong D. Staphylococcus epidermidis septicemia in children with leukemia and lymphoma. Am J Dis Child. 138:1984;715-719.
2. von Eiff C., Proctor R.A., Peters G. Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med. 110:2001;63-64.
3. Sohn A.H., Garrett D.O., Sinkowitz-Cochran R.L., Grohskopf L.A., Levine I.L., Stover B.H.et al. Paediatric Prevention Network. Prevalence of nosocomial infections in neonatal intensive care unit patients, Results from the first national point-prevalence survey. J Pediatr. 139:2001;821-827.
4. Lyytikäinen O., Lumio J., Sarkkinen H., Kolho E., Kostiala A., Ruutu P. Hospital Infection Surveillance Team Nosocomial bloodstream infections in Finnish Hospitals during 1999-2000. Clin Infect Dis. 35:2002;14-19.
5. Bromiker R., Arad I., Peleg O., Preminger A., Engelhard D. Neonatal bacteremia patterns of antibiotic resistance. Infect Control Hosp Epidemiol. 22:2001;767-770.
6. Raymond J., Aujard Y. Nosocomial infections in pediatric patients: a European multicenter prospective study. Infect Control Hosp Epidemiol. 21:2000;260-263.
7. Diekema D.J., Pfaller M.A., Schmitz F.J., Smayevsky J., Bell J., Jones R.N.et al. Sentry Participants Group Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibilities of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the Sentry Antimicrobial surveillance program, 1997-1999. Clin Infec Dis. 32:2001;S114-132.
8. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 29:1999;239-244.
9. Tacconelli E., Tumbarello M., Donati K.G., Beltio M., Spanu T., Leone F. Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: Epidemiological and clinical findings from a case-control study. Clin Infect Dis. 10:2001;1628-1635.
10. Petinaki E., Kontos F., Miriagou V., Maniati M., Hatzi F., Maniatis A.N. Bacterial Resistance Study Group Survey of methicillin-resistant coagulase-negative staphylococci in the hospital of central Greece. Int J Antimicrob Agents. 18:2001;563-566.
11. Spencer R.C. Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis. 15:1996;282-285.
12. Wilson A.P.R., O'Hara M.D., Felmingham D. Teicoplanin-resistant coagulase-negative Staphylococcus. Lancet. 2:1986;973.
13. Sieradzki K., Villari P., Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother. 42:1998;100-107.
14. Goldstein F.W., Coutrot A., Sieffer A., Acar J.F. Percentages and distribution of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother. 34:1990;899-900.
15. Schlegel L., Saliba F., Mangeny N., Mathieu D. Pulsed field gel electrophoresis typing of coagulase-negative staphylococci with decreased susceptibility to teicoplanin isolated from an intensive care unit. J Hosp Infect. 49:2001;62-68.
16. Woodford N., Johnson A.P., Morrison D., Speller D.C.E. Current perspectives on glycopeptide resistance. Clin Microbiol Rev. 8:1995;585-615.
17. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990 June;34(6):1227-31.
18. Hiramitsu H., Kasmierczak A., Lucht F., Tremeaux J.C., Chavanet P., Duez J.M. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection. 13:1985;S123-S128.
19. Portier H., Kasmierczak A., Lucht F., Tremeaux J.C., Chavanet P., Duez J.M. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infect. Chemother. 34:1990;227-231.
20. Barr K, Hanaki H, Ino K, Yabuto K, Oguri T. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 1990 Nov;9(11):804-9.
21. Portier JG, Smith ETM, Hogg GM. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against.
22. Totsuka K., Shiseki M., Kikuchi K., Matsui Y. Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. J Antimicrob Chemother. 44:1999;455-460.
23. Climo M.W., Patron R.L., Archer G.L. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother. 36:1999;1747-1753.
24. Domaracki B.E., Evans A.M., Venezia R.A. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother. 44:2000;1394-1396.
25. Wiseman L.R., Lamb H.M. Cefpirome: a review of its antibacterial activity, Pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs. 54:1997;117-140.
26. Seibert G., Isert D., Klesel N., Limbert M., Markus A., Schrinner E. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob. Chemother. 29:1992;25-30.
27. Marton A., Major P. In vitro susceptibility of Streptococcus pneumoniae strains to nine β-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin. Microbial Drugs Resistance. 3:1996;361-369.
28. Raymond J., Vedel G., Bergeret M. In vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase negative staphylococci. J Antimicrob Chemother. 38:1996;1067-1071.
29. Bergeret M., Raymond J. In vitro-bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus. J Antimicrobial Chemother. 43:1999;291-294.
30. Vedel G., Bouchet E., Gangneux J.P., Nevot P. A simple micro-method for time-kill studies amenable to routine laboratory use. J Antimicrobial Chemother. 37:1996;842-844.
31. Ackerman B.H., Vannier A.M., Eudy E.B. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother. 36:1992;1766-1769.
32. Drugeon HB, Caillon J, Juvin ME, Picault JL. Bactericidal activity of cefpirome-fosfomycin in comparison with cefotaxime-fosfomycin against Staphylococcus aureus. In: Abstracts of the 17th International Congress of Chemotherapy, Berlin, 23-28 June 1991. Munich: Futuramed [Abstract 256].
33. Simon C., Simon M. In vitro activity of flomoxef and cefazolin in combination with vancomycin. Infection. 19:1991;S276-S278.
34. Rochon-Edouard S., Pestel-Caron M., Lemeland J.F., Caron F. In vitro synergistic effects of double and triple combinations of β-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 44:2000;3055-3060.
35. Proctor R.A., Wick P., Hamill R.J., Horstmeier P., Guillings-Handley J., Weisensel M.et al. In-vitro studies of antibiotic combinations for multiple-resistant coagulase-negative staphylococci. J Antimicrob Chemother. 20:1987;223-231.
36. Hollenstein U., Brunner M., Mayer B.X., Delacher S., Erovic B., Eichler H.G.et al. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin Pharmacol Therap. 67:2000;229-236.
37. Nahata M.C., Barson W.J., Puri S.K. Pharmacokinetics of cefpirome in pediatric patients. Antimicrob agents Chemother. 39:1995;2348-2349.
38. Aritaka N., Hanaki H., Cui L., Hiramatsu K. Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother. 45:2001;1292-1294.
39. Sieradzki K., Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol. 179:1997;2557-2566.